In this episode, we’re joined by Pablo Hofbauer, co-founder of HeartBeat.bio and a leading innovator in self-organizing cardiac organoids, known as cardioids. Pablo shares his journey into biotechnology and explores how cardioids are transforming cardiac drug discovery. We discuss their applications in studying genetic mutations, the significant advantages they offer over traditional 2D models, and their potential to inform future therapies. Pablo also provides insights into the complex process of commercializing scientific research, covering topics from patent strategies to funding challenges. Additionally, he highlights the impact of AI and robotics in enhancing research at HeartBeat.bio. This episode offers an exciting insight into heart health and the evolving landscape of biotech innovation.
00:00:49 Introduction to Pablo
00:02:45 What are cardioids?
00:03:59 The Role of Personalised Medicine
00:05:14 Mutations Studies using CRISPR Genetic Engineering
00:08:03 Traditional 2D models vs 3D models of the Heart Chamber
00:13:04 Cell therapy: Pig Heart Transplanted
00:15:06 Future Potential Therapies
00:17:52 Challenges in Commercialisation of Research
00:19:10 Intellectual Property - Patents
00:20:20 Securing funding - Scientific Pitching
00:21:55 Company Partnerships - Robotics
00:23:32 Hitting Milestones
00:26:03 Artificial Intelligence and Machine Learning
00:27:35 Advice for Aspiring Scientists